中性粒细胞数作为心血管疾病的危险因素:我们如何管理它?
Stefano De Servi1, Antonio Landi2,3, Elena Gualini4
1Department of Molecular Medicine, University of Pavia, Pavia.
Journal of cardiovascular medicine (Hagerstown, Md.)
|September 30, 2024
概括
高中性粒细胞计数是动脉样硬化心血管疾病的因果风险因素. 抗血小板药物克洛皮多格勒可以通过减少中性粒细胞数量来提供心血管益处.
科学领域:
- 心血管科学 心血管科学
- 免疫学 免疫学 免疫学
背景情况:
- 中性粒细胞激活是动脉样硬化斑块发育,进展和破裂的组成部分.
- 门德尔随机化研究证实高中性粒细胞计数是动脉样硬化心血管疾病的因果风险因素.
- 实验数据表明,中性粒细胞枯竭阻碍了斑块的发展.
研究的目的:
- 审查当前证据,将中性粒细胞数量与心血管疾病发展联系起来.
- 探索克洛皮多格雷尔在降低中性粒细胞数量方面的潜在有益的非目标效应.
主要方法:
- 审查最近的实验和流行病学研究.
- 对克洛皮多格雷尔对炎症标志物和中性粒细胞水平的已知影响的分析.
主要成果:
- 中性粒细胞数量与动脉样硬化心血管疾病有因果关系.
- 克洛皮多格雷尔是一种抗血小板药物,可降低中性粒细胞数量和炎症标志物.
- 克洛皮多格雷尔对中性粒细胞的这种降低可能是额外的治疗益处.
结论:
- 中性粒细胞数量是心血管疾病发病的一个重要因素.
- 克洛皮多格雷尔降低中性粒细胞数量可能有助于其预防缺血事件的有效性.
相关概念视频
Inflammation
53.2K
Overview
53.2K
Coronary Artery Disease IV: Medical Management
11
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
11
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
63
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
63
Coronary Artery Disease I: Introduction
3
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
3
Disorders of Leukocytes
902
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
902
Atherosclerosis III: Management
2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2


